Literature DB >> 6188365

Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia.

T L Andres, M E Kadin.   

Abstract

We attempted to determine the reliability of surface markers in distinguishing 21 small round cell tumors from lymphoid malignancies. Using immunofluorescence on tumor cell suspensions and immunoperoxidase on fresh frozen sections, we found that specimens of neuroblastoma (n = 7), rhabdomyosarcoma (n = 7), Ewing's tumor (n = 5), and two unclassified small round cell tumors all lacked human HLA-DR antigens. Each of eight tumors tested also lacked common leukocyte antigen (T200). In each of 13 cases studied, neither polyvalent surface immunoglobulin (sIg) nor receptors for sheep erythrocytes (E), complement (EAC), or the Fc portion of IgG immunoglobulin (EA) were found. Conversely, we found HLA-DR and/or T200 antigens, usually one or more receptors for E, EAC, or EA, and not infrequently, monoclonal sIg on malignant cells in each of 42 cases of lymphocytic lymphoma and leukemia. We conclude that study of surface DR and T200 antigens, sIg, and receptors for E, EAC, and EA aids the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6188365     DOI: 10.1093/ajcp/79.5.546

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  9 in total

1.  Conditioning with α-emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation.

Authors:  Brian Kornblit; Yun Chen; Brenda M Sandmaier
Journal:  Chimerism       Date:  2012-04-01

2.  Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.

Authors:  Raya Mawad; Ted A Gooley; Joseph G Rajendran; Darrell R Fisher; Ajay K Gopal; Andrew T Shields; Brenda M Sandmaier; Mohamed L Sorror; Hans Joachim Deeg; Rainer Storb; Damian J Green; David G Maloney; Frederick R Appelbaum; Oliver W Press; John M Pagel
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-20       Impact factor: 5.742

3.  Pretargeted radioimmunotherapy for hematologic and other malignancies.

Authors:  Roland B Walter; Oliver W Press; John M Pagel
Journal:  Cancer Biother Radiopharm       Date:  2010-04       Impact factor: 3.099

4.  Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation.

Authors:  Yun Chen; Brian Kornblit; Donald K Hamlin; George E Sale; Erlinda B Santos; D Scott Wilbur; Barry E Storer; Rainer Storb; Brenda M Sandmaier
Journal:  Blood       Date:  2011-12-01       Impact factor: 22.113

Review 5.  Radioimmunotherapy-based conditioning regimens for stem cell transplantation.

Authors:  Michelle M Zhang; Ajay K Gopal
Journal:  Semin Hematol       Date:  2008-04       Impact factor: 3.851

6.  Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.

Authors:  Johnnie J Orozco; Tom Bäck; Aimee Kenoyer; Ethan R Balkin; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Shani L Frayo; Mark D Hylarides; Damian J Green; Ajay K Gopal; Oliver W Press; John M Pagel
Journal:  Blood       Date:  2013-03-07       Impact factor: 22.113

7.  Radiolabeled antibodies directed at CD45 for conditioning prior to allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Johnnie J Orozco; Jill Zeller; John M Pagel
Journal:  Ther Adv Hematol       Date:  2012-02

8.  Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.

Authors:  Hirohisa Nakamae; D Scott Wilbur; Donald K Hamlin; Monica S Thakar; Erlinda B Santos; Darrell R Fisher; Aimee L Kenoyer; John M Pagel; Oliver W Press; Rainer Storb; Brenda M Sandmaier
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

9.  Addition of Astatine-211-Labeled Anti-CD45 Antibody to TBI as Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model: "Radioimmunotherapy to Overcome Transfusion-Induced Sensitization".

Authors:  Aya Nakaya; Huiying Qiu; Erlinda B Santos; Donald K Hamlin; D Scott Wilbur; Rainer Storb; Brenda M Sandmaier
Journal:  Transplant Cell Ther       Date:  2021-02-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.